H1N1 influenza outcome in rheumatic patients under biological therapy

Clinical and Experimental Rheumatology

Volumn 30, Issue 2, 2012, Pages 311-312

  Bournia, V K ^a   Sfontouris, C ^b   Konsta, M ^a   Iliopoulos, A ^a  

^a Veterans Administration Hospital NIMTS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OSELTAMIVIR; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIGEN DETECTION; BIOLOGICAL THERAPY; CLINICAL EVALUATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG FATALITY; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INTENSIVE CARE UNIT; LETTER; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SEASONAL INFLUENZA; THROAT CULTURE; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; FEMALE; GREECE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863772875     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. KAPETANOVIC MC, SAXNE T, NILSSON J-Å, GEBOREK P, Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007; 46: 608-11.
2. GELINCK LBS, VAN DER BIJL AE, BEYER WEP et al.: The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-6.
3. GABAY C, BEL M, COMBESCURE C et al.: Impact of synthetic and biological disease modifying antirheumatic drugs on antibody responses to the ASO3-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, singlecenter study. Arthritis Rheum 2011; 63: 1486-96.
4. SHALE M, CZUB M, KAPLAN GG, PANACCIONE R, GHOSH S: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Therap Adv Gastroenterol 2010; 3: 173-7.
5. SERRATO VA, AZEVEDO VF, SABATOSKI V, GONCALVES BP, MACHADO DM: Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report. Clin Rheumatol 2010 Mar 5 [Epub].
6. KLING MC, LARIAN AA, SCORDI-BELLO I, EMER J,;1; LEBWOHL MG: Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab. Arch Dermatol 2010; 146: 651-4.
7. Weekly;1; Report on Epidemiologic Monitoring of Influenza (26 May 2010). Athens, Greece, Hellenic Centre for Diseases Control and Prevention-Ministry of Health and Social Solidarity; 2010.
8. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study